Adaptive Biotechnologies is a commercial-stage company developing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s clinical diagnostic product, clonoSEQ, is authorized for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia and is also available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. Using its collaboration with Microsoft Corporation, Co. is creating a map of the interaction between the immune system and disease. The ADPT average annual return since 2019 is shown above.
The Average Annual Return on the ADPT average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADPT average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADPT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|